Characteristics of participants
SCLC
ONCOLOGY, SMALL CELL LUNG CANCER, SCLC
From March 2019 to March 2022, eligibility screening was conducted for 32 advanced SCLC cases with no progression through first-line therapy (Fig. 
Study flowchart
Baseline characteristics of the participantsITT: intent-to-treat; PP: per-protocol; ECOG PS: Eastern Cooperative Oncology Group Performance Status; ES-SCLC: extensive-stage small cell lung cancer